Characterizes BcStc5 as an eudesmanediol synthase, resolving biosynthetic controversy.
, achieving titers >550 mg/L. This work resolves a long-standing biosynthetic controversy, characterizing BcStc5 as an eudesmanediol synthase rather than the ABA cyclase, settling the controversy over this protein.
No takes yet. Share an insight, caveat, or question.
Coca-Ruiz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: